Get 99% OFF here : http://ulyrics.us/
Get 99% OFF here : http://ulyrics.us/
Get 99% OFF here : http://ulyrics.us/
AK Computer Network
Have Done This Video
Đăng ký:
Đăng Nhận xét (Atom)
-------------------------------------------
Bruna Karla - 🔔 Tum Tum | Bruna Kids - Duration: 3:29.
For more infomation >> Bruna Karla - 🔔 Tum Tum | Bruna Kids - Duration: 3:29. -------------------------------------------
Former Homeland Security Official ATTACKS Our Show For Telling The Truth - Duration: 10:14.
Recently, Suzanne Spaulding, a former under secretary at the Department of Homeland Security,
took some time to attack our program, America's Lawyer on RT America.
Saying that we're harming the United States by pointing out the flaws in our justice system.
Turnabout is fair play.
So we did some digging into Ms. Spaulding's past and found out what really wasn't surprising
at all.
As a matter of fact, there are stories that both Farron and I have reported over the years
time and time again.
Farron, this is...
I look at this story.
They come out against our RT because we're reporting about fracking.
We're reporting about Wall Street banks stealing millions of money from mom and pop investors.
We're coming out against corporations that are polluting us out of existence.
We're coming out against corporations that are contributing to climate change.
We're coming out with, I mean just story after story that is just telling the truth.
And they said, oh my God, this is a vast Russian conspiracy and Putin is behind what I'm doing
and what you're doing now.
You know, basically this is some vast... they even make the suggestion that Ring of Fire
is owned by RT, which it's not.
There's no ownership issue here this.
But as I looked at this story, here's what I thought about.
I thought about the stories that you have written about and stories that you've reported
about for years.
And that is, that what we used to think, well, did you ever see the movie, I think it's Wag
the Dog?
Right.
And Wag the Dog was about the arms industry churning up war.
Okay.
And I started looking at Ms. Suzanne Spaulding.
And we started looking about, what's her background?
Why don't you take it there and I'll add as we go, okay.
Well, as you mentioned previously she did some time as an under secretary at Homeland
Security.
Her big thing was cyber security.
And during that time she, you know, managed this $3 billion budget for this entire organization,
but she was also working with CEOs, working with corporations, trying to always tell them
the next big threat is right around the corner.
And then when she left Homeland Security, that became her full time job.
That's where she makes her money.
Yeah.
Is telling corporations, and I'm assuming I'm positive this is someone who still has
her security clearance.
That's how she makes money.
Right, that's a big selling point for anybody looking to hire her.
Right.
So she goes out there and this was what she did during this speech.
She says, listen, RT America is trying to undermine the United States by pointing out
all of our flaws.
She didn't even dispute that it was accurate.
She just said there, they're talking about all the bad things we do in this country.
And that's part of Putin's plan somehow, by showing people what's real versus the corporate
censored news.
In other words, when you and I get on RT and we talk about the fact that today Wells Fargo
has to pay another billion dollars from stealing from American consumers.
She thinks that's bad because we're undermining the system.
When we go on RT and we talk about the fact that judges are now owned and operated by
conservative GOP corporate types, that's bad for the system.
Look, this woman is nothing but a war pimp.
Right.
And the organization she works for are nothing but war pimps.
And the people she's surrounded herself are nothing but war pimps.
When I read, when I, when we actually did research, and this is just by the way we've
just started with this research and we've just started with these stories, but I take
a look at who does she speak to?
Do you see anything in here where she gives speeches to environmental organizations?
Or advocacy groups for consumers?
Or groups that are out there looking out for the interest of taxpayers?
No, her speeches to Goldman Sachs, Exxon, Boeing, McDonnell Douglas, DuPont, Dow.
She is just one of them.
She is nothing more than a puppet for these organizations and she happens to have a clearance,
a security clearance.
So all of a sudden these organizations that are saying, oh my God, RT is actually talking
about us.
She gets upset because she's paid to get upset.
Exactly, and this group that she's with, this is the group she gave the speech for, she's
a fellow here; the Center for Strategic and International Studies.
They actually boast about being one of the most influential, in terms of being embedded
with the defense contractors, with the Pentagon.
They actually get funding.
She's bragging about it.
Yeah, they get funding from the Department of Defense.
This group that she is with, they get funding from the government.
So she's out hear spreading this propaganda like they want her to, to corporations.
So they pay more money.
She's paid to do it.
Right.
Okay.
She's part of this Aspen group.
Did you follow?
I looked at the Aspen group.
Did you take a look at it?
Yeah.
The Aspen group, if you were to put a room full of people that look like a setting out
of Dr. Strangelove.
Like we will bomb you into nonexistence.
It is that group.
The people that are funding her, the people that are paying Suzanne Spaulding's way, are
Lockheed.
They're Northrop.
They're Boeing.
This, the list is right here.
Yeah.
They're General Dynamics.
They're Raytheon.
And so again, you have this element that are what I call the HillaryBot holdovers.
And the HillaryBot holdovers buy into this because everything that is Russian is bad.
And so these folks are the folks that would gladly start conflict with Iran.
They would start conflict with China.
They would gladly start a new cold war with Russia.
They would start a new cold war, a new war anywhere in the world because that's how they
make their money.
Except I actually, I have to correct you on this because the one place they're not going
to start a war is Saudi Arabia and the United Arab Emirates
There you go.
Because they're also getting money from them.
The groups that Suzanne Spaulding is with is taking money from those countries, so the
ones that are the real enemies, not just of the United States, but of humanity in general,
while they're paying them, they're also buying $20 billion in weapons right now.
Can you imagine going around giving speeches that these, these TV shows, like the one we
do, where we talk about bad judges that are just in the pocket of Corporate America.
We talk about the dynamics of the war industry wanting to chum up war by fear.
By saying, oh my God, you know, if we're not careful, China is gonna to stomp on us.
If we're not careful, Iran's going to have another nuclear bomb tomorrow.
They are in the business of war and I tell you, if you have any doubt that this actually
exists, there really is a, it's a fictional movie, but it's called Wag the Dog.
Take a look at Wag the Dog and you then understand what these folks are all about.
Again, there's no higher calling here.
Suzanne Spaulding is not operating with any kind of higher calling.
She's operating on; the only calling is, is when the Arab Emirates wants to give her a
million dollars for making a tour and talking about, you know, the threat of Iran or whatever
it may be.
She's taking the money.
When Northrop, or when, I have the list right here, by the way.
When Boeing, General Dynamics, Raytheon, DuPont, Exxon, when these companies want her to give
a speech, she does it.
She doesn't give a speech for advocacy groups.
You will never find Suzanne Spaulding giving a speech for an environmental activist group
because according to Suzanne, they want to undermine the sanctity of the judicial system
in America.
You'll never see her giving a speech for a consumer group that says by God, pharmacy
costs need to come down because according to Suzanne Spaulding and all of the little,
the gremlins, the flying monkeys that she works with, they would determine, oh by God,
the Russians are trying to undermine the American justice system.
Do you see it any other way?
Absolutely not.
And she's also, you know, Chevron, Exxon, Saudi Aramco.
Those are other companies that are funding these groups that she works for and that she
speaks on behalf of.
I mean, this is, this woman is so embedded in both the military industrial complex; with
the climate change denying complex.
She's served in both Republican and Democratic administrations.
This is everything that is wrong with this country.
She was a key advisor to the CEOs... now listen to this.
If you're watching this show, go look at what the business round table is.
The business round table are, they're nothing more than this gaggle of corporate CEOs who
want to take more money from Americans and want to do it however they can get by, whether
it's breaking the law, whether it's change in law, whether it's stacking the court system
with right wing corporate judges, they're going to do it.
Now, there's more to this story.
Let's pick it up in another segment.
Absolutely, and just to add an exclamation point on that.
If anybody isn't familiar with the business round table, they are the US Chamber of Commerce
on steroids.
The worst of the worst from that organization is who's made up the business round table
there.
So Suzanne Spaulding, welcome to Ring of Fire that, oh by the way, is not owned by the Russians.
Get ready for more Suzanne Spaulding.
-------------------------------------------
Live PD: The Odd Couple (Season 3) | A&E - Duration: 4:20.
For more infomation >> Live PD: The Odd Couple (Season 3) | A&E - Duration: 4:20. -------------------------------------------
Forged in Fire: The Navaja Tests (Season 5, Episode 9) | History - Duration: 4:45.
For more infomation >> Forged in Fire: The Navaja Tests (Season 5, Episode 9) | History - Duration: 4:45. -------------------------------------------
5 ASTONISHING ADVANCEMENTS IN HEALTHCARE - Duration: 11:53.
Hey everyone, welcome to another exciting technology video
There's no question that technology is dramatically changing both the world around us and our individual lives
One area where technology has already dramatically changed our lives and yet still holds a seemingly endless amount of potential is the world of healthcare
While we're still a few years away from being able to live forever for this video
We've picked out five companies that are making incredible advancements in healthcare and biotechnology right now
2018 has seen more biotechnology acquisitions than ever before
public interest continues to rise as new and exciting technologies and advancements become reality and
Even more thrilling avenues of research and development are revealed
For today's selections, we've covered a wide range of companies focusing on different areas
including the use of artificial intelligence to improve medical imaging AI enhancements of long-term care and the electronic health record a
3d bioprinter for life sciences companies a
company focused on robot-assisted surgery
And a bio labs startup company that's developing home cryopreservation kits
Without further ado. Let's dive into the video
Getting things started on our list we've got zebra medical imaging
Zebra is on a mission to provide
radiologists with the tools to make a huge leap forward in patient care
Medical imaging is one of the most critical services in the field and demand is rapidly outpacing supply with less qualified
radiologists than necessary to maintain quality patient care
This is where zebra comes into the equation
by empowering radiologists with the revolutionary ai1 technology
They help health providers manage the consistently increasing workload without compromising quality
They do this by using millions of imaging and related clinical records to build high-performance
Algorithms that can automatically detect medical conditions quickly and accurately
They fully expect that the effectiveness of these algorithms will can in you to increase overtime
With automated findings and insights occurring in parallel to diagnosis
Zebra is transforming patient care in a number of ways. They're identifying high-risk patients earlier
facilitating disease prevention programs
Optimizing worklist prioritization for urgent cases and they're managing population health problems to help reduce the costs of care
the zebra radiology assistant receives imaging scans from a variety of
modalities and then it automatically analyzes them to produce different clinical findings which are provided in real time to
Radiologists or other physicians and hospital systems as necessary
they employ a
proprietary database filled with millions of imaging scans so that their deep learning and machine learning tools can create software solutions by
Analyzing the data in real time with a human level of accuracy
Moving on to number four on our list
We've got matrix care a company offering certified long-term care electronic health record EHR solutions
Matrix care is the complete solution for growing organizations that need to find ways to successfully manage risk in care delivery
across the long-term post-acute care spectrum
They have become a trusted name in the world of health care helping companies to connect collaborate and prosper through regionally-based
fully integrated fee for value health care systems
Matrix care solutions have powered the long term care continuum for over 30 years and are now the largest long-term post-acute care
Technology provider and have become the first to offer a true fully integrated full spectrum EHR solution
Matrix care is the only provider of long-term care software and technology that offers a true full spectrum solution
With a substantial client base in every segment of the market from skilled nursing to senior living life planning communities and home care
Organizations they have a clinical EHR solution to meet the unique work and requirements of a variety of workplaces
by purpose building person centric solutions that are both by and for experts in senior living they are
Consistently able to help deliver superior services while maximizing overall operating margins
Efficient information management is truly one of the most important elements in our path to a healthier future
Up next at number three we move on from the world of increasingly efficient information
To the realm of robotic assisted medicine with maser robotics
Their vision is to enhance the power of healing through innovation and their mission is to develop and introduce
revolutionary robotic based technology and products aimed
redefining the gold standard of quality care
Their name maser is a term that means healing or cure in Hebrew and with their innovative global
spine and brain surgery products maser X and Renaissance
They are elevating the art of spine and brain surgery from the typically freehand procedures that they are now to cutting-edge state-of-the-art
surgical procedures that define the future of Surgical Technology
Lasers core technology is the collaboration of four key pillars in their system to provide predictable
efficient and precise surgical procedures it
Starts with their precise surgical planning suite comprised of sophisticated 3d analytics and virtual tools to develop
Procedural goals and a comprehensive surgical blueprint which separates the analytical planning process from the actual surgery
The anatomy recognition engine technology reads images and identifies anatomical features based on their advanced
Proprietary algorithms serving a fundamental function in planning things like vertebral segmentation image registration
and alignment calculations
The third pillar the patient connection platform is a set of
Biocompatible devices that rigidly afix the robotic systems arm to the patient's skeletal Anatomy during surgery
Ensuring precision with a stable solid connection that maintains patient machine unity during operation
The final pillar is the cross modality image registration
system a
Sophisticated tool with the ability to analyze and match images from different modalities and body positions and register the vertebra
independently
Moving on to number two, we've got the incredible world of bio printing
specifically that performed by the innovative company selling
selling focuses on the development and commercialization
Of bio printing technologies that allow researchers to 3d print human organs and tissues for the development of pharmaceutical and cosmetic
products with the intention of moving forward towards clinical applications in the future
Their success is driven by their innovative and patent-pending biowing a biomaterial
Innovation that has enabled human cells to grow and thrive just like they would in a natural human body environment
Their platform is currently being used to print tissues like liver cartilage and skin as well as fully functional cancer tumors
Which can then be used in the development of new treatments in?
a span of twelve months they've succeeded in commercializing
products in over 40 countries while selling products in hundreds of prestigious labs around the world
One of the most spectacular offerings available from selling is their line of incredible Plus 3d bio printers
designed to be the future of 3d bioprinting
Initially the printer comes optimized to print skin or cartilage tissue
but it can be endlessly adjusted and customized making the only limits your imagination a
Robust and reliable device the incredible plus 3d is the only true benchtop bio printer currently available on the market
It is perfect for bio printing human tissues and tissue models forever advancing research applications
And it has consistently led to increasing research productivity in a wide range of applications
The incredible plus 3d is a nomadic based extrusion bio printer with dual print heads and a UV
Led curing system designed for bio printing complex human tissue models and organs for tissue engineering research
It is designed to be cost effective and thanks to the patented clean chamber technology. It can be used right on a lab bench
the HEPA filtered positive air pressure inside the printing chamber
Ensures that the bio printing remains sterile and it works through a bottom-up layer-by-layer fashion
Number one on our list of five companies making astonishing advancements in health care is acorn bio labs a
Canadian biotech start-up focused on helping you to preserve your very own cells for future therapeutic applications
as we've seen throughout this video the frontier of
biotechnology has begun to deliver incredibly powerful new healthcare innovations each with their own potential to
Dramatically improve our health span the portion of our life during which we're fully healthy
Their vision for the future is based on the advancements being made in the fields of gene therapy
stem cell therapeutics tissue engineering and organ regeneration
all of which will make the services that acorn provides increasingly valuable in the near future, so
What exactly is the Acorn surface?
essentially it allows you to freeze the clock by cryo preserving a sample of your cells before they accumulate the
irreversible damage that occurs as you age
Acorn is the first take-home human cell cryopreservation service and they offer a number of distinct advantages
By freezing the cells when you're young and keeping them safe and viable
They'll be compatible with future medical techniques as they're developed and become necessary
The take home kit allows you to collect the cells yourself in the comfort of your own home without having to involve doctors or medical
professionals all in a very non-invasive manner
There cell testing protocols ensure that your cells arrive in the lab in top-notch condition and then later in life when you need those younger
Cells you'll be able to use them with advanced therapeutics
They also go another way to keep you fully informed on all the latest advancements in biotechnology. So you won't miss out on a thing
Well that does it for today's video covering five companies that are producing astonishing advancements in health care as we speak
From implementation of artificial intelligence and health information management to robotic surgery
3d printing and
Cryopreservation of cells the future is bright
These advancements will help to ensure that we're not just extending our lifespan
But we're also spending more of our lives in a state of good health
Do you think we missed out on a super cool healthcare advancement? If so, let us know in that comment section down below
If you enjoyed checking out our video then please make sure you hit the like button and the subscribe button and then share it around
on social media
Hit the bell icon to ensure you get a notification every time we upload a new video breaking down the latest and greatest
advancements in technology
From all of us here at techno nerd. Thanks for watching
-------------------------------------------
How to Identify Winning Stocks (and Avoid Losers!) - Duration: 5:22.
David Gardner: Mailbag item No. 3. Andy, let's do it! This one comes from Australia.
Colin Anderson writes in, "Dear Motley Fool team, since joining Motley Fool Stock Advisor
and Rule Breakers in the U.S. and Stock Advisor and Dividend Investor here in Australia, all
Motley Fool services, in the last four years, I've become an educated, enriched, and entertained investor.
I'm especially," he's going to keep going with the alliteration here, "I'm especially
wiser, wealthier, and wwwwwwwwell prepared [ugh] for market volatility.
During the recent bumpy ride through the past few months, I've slept well, been quite relaxed,
but a little sad that my liquidity didn't allow me to buy more in the dip."
He didn't write "on the dip." Here in America, we say "buy on dips."
This is, maybe, an Australian English approach here, buying in the dip.
Andy Cross: Could be! Gardner: We'll get back to that in a little bit.
Let's continue.
"Your services point me towards better companies, better investing, and a better future.
Thank you for all the fantastic services. Now, to my question.
I used to wait until I accumulated about $5,000 before investing in any stock.
That was the limit my old broker set before bumping his charges from $50," that's the
commission rate, "to 1% of the purchase price. Ouch.
My new broker now charges," this is the better world we're living in now, "$15 flat.
Still high by U.S. standards, but better." Certainly, we agree.
"Thanks to some great tips from you all, I've started to dollar-cost average my entry into a new stock."
We just talked about that. Regular investment, adding to winners.
"In my old style, I bought bigger chunks and often added to my weeds as I tried to lower
my average purchase price. I lost bigger than I would have lost in the Foolish style of investing.
But even with your sage advice, I've only learned the painful lessons of watering weeds this year.
I recently started small positions in Intuitive Surgical, Shopify, MongoDB, PayPal, and JD.com.
I've added to Shopify and MongoDB.
Now, the recent slide in the market has opened up a question: do I buy," here it is again,
Andy, "in the dip? Or, would I be watering my weeds again?
In my specific case for these current stocks," the ones I just mentioned, Intuitive Surgical, etc.,
"I have confidence in these companies.
The reasons for selecting them have been Foolish, not foolish.
The market drop has been a vote against the broader market.
I've seen nothing against the weight of these companies.
But how do I recognize a dip or distinguish it from a developing weed?
Yours Foolishly, Colin Anderson." Andy, I laid a lot of scaffolding there.
Colin shared where he is in his investment journey.
But fundamentally, the question is this: when a stock drops that we like, how do we know
whether it's just dipping and going to come back or one of those weeds that you don't
want to keep watering? Cross: It's a great question, Colin.
Making the distinction between watering your weeds -- and when we say "weeds," we mean,
at least I mean, and I hope Colin means this, as well, companies that have a lower stock
price, and maybe the business has deteriorated a little bit, and it's a smaller part of our
portfolio, so we are dollar-cost averaging our price down a little bit.
Gardner: A lot of people do that! Cross: A lot of people do it.
Gardner: But Andy, you and I know, the reason we call them weeds is, those are the ones
that you shouldn't have done that to. Cross: That's exactly right.
Gardner: You don't want to water the weeds. Cross: You don't want to water the weeds.
The full saying is "water your weeds and trim your flowers."
You actually want to water your flowers, because those are the businesses that are going to
continue to hopefully win in life and support the great things they are doing around the world.
Also, that's good for shareholders.
Supporting those businesses and investing your hard-earned capital into the businesses
that are doing well.
Now, to your question, the difference between watering weeds and watering businesses like
Intuitive Surgical and Shopify, that have gone down, that have pulled back.
The first thing I would say is, has the market pulled back in general?
Is whatever general market index you look at -- and certainly, the last couple of months,
the S&P 500, the most general market followed here in the U.S., it's different around the world.
In Australia, it's the ASX 200. Whatever it might be. The general market, has that pulled back as well?
Have my stocks pulled back with that?
So, first of all, how has your stock performed against the general market?
Gardner: Right. If the whole market's selling off and your stock's with it, that probably doesn't indicate
they're weeds.
Cross: Not by itself, it certainly doesn't. Gardner: Right. The whole market sold off.
Cross: That's right, exactly! That's the first thing.
The second thing is, then, look at the performance of your businesses. Go in and see.
You can go on fool.com, the fool.com over in Australia, and pull up a ticker to see
if the business continues to grow.
If the business seems to continue do well, as Intuitive Surgical is, as Shopify is,
as so many of our businesses continue to do, then I would see that as an opportunity to
add on that weakness in price. But hopefully, you're adding on the strength of the business.
That's the difference.
-------------------------------------------
President Donald Trump Impeachment Inquiry Is 'Inevitable,' Chuck Todd Says | Sunday TODAY - Duration: 4:53.
For more infomation >> President Donald Trump Impeachment Inquiry Is 'Inevitable,' Chuck Todd Says | Sunday TODAY - Duration: 4:53. -------------------------------------------
Adam Ruins Everything - How the Government Created Tech Monopolies | truTV - Duration: 2:22.
Ah, yes, we've all heard that myth:
the solitary tech innovator,
the genius singlehandedly changing the world.
But it's way wrong.
Tech companies are actually taking over the world.
And they're doing it with our government's help.
Here at CORI, we're harnessing
innovation, so that we can make
the world a better place
all by ourselves.
Hey, bruh. You need any help
or taxpayer money or whatever?
Dude!
Not right now! Cut!
(bell rings)
(man) All right, everybody, let's take five.
Todd had help?
Not just Todd,
all of Silicon Valley benefits from government money.
And sometimes even government technology.
In fact, the US government invented the fundamental tech
that became the internet.
Hey, who wants to use this cool new technology I invented
that connects computers?
♪♪
Uncle Sam also gave a $4.5 million grant
to the search engine that eventually became Google.
And a half a billion dollar government loan jumpstarted
the release of Tesla's first car.
Thanks, man.
We'll totally pay you back
with, like, making people's lives better
or more convenient, or...
I don't know, whatever.
But why would Todd, I mean, tech companies,
say they did it all on their own?
Because it lets them pretend they don't owe us anything.
Let's be clear, the problem isn't that tech moguls
took money from the government,
it's that while these companies
we invested in rake in billions,
taxpayers like you and me are getting screwed.
Normally, if you invest in a company,
you get to make money when the company profits.
But that's not the relationship we taxpayers
have with Big Tech.
In fact, quite the opposite.
(laughter)
Tech companies are infamous for funneling funds
through places like the Cayman islands,
Luxemburg, and Ireland
to avoid paying their fair share of taxes.
Hey, guys, any chance you can chip in for that 'za?
Or like the roads the pizza driver used to get here?
Sorry, dude, all our cash is in Ireland.
(laughter)
-------------------------------------------
What is an Inverted Yield Curve, and Does it Predict a Recession? - Duration: 4:51.
Chris Hill: You and I were talking this morning about something that has gotten some attention
this morning. I wanted to get your thoughts on this.
It's something that we rarely, if ever, talk about on this podcast.
Emily Flippen: Well, it rarely, if ever, happens. Hill: Fair point! But, the yield curve.
Explain to the dozens of listeners what's happening today.
Flippen: Sure. We say today that the yield curve on the five-year Treasury note fell below the three-year note.
Essentially, what we normally see happen is, if you're going to lock your money up for
five years, you're going to demand a higher premium than if you do three years.
It's strange, if ever, when it happens that a three-year note has a higher yield than
a five-year note, or a 60-day bond to a 10-year bond.
It's just stuff that, when you think about a market, shouldn't happen.
When this happens, it's considered by many investors a very strong predictor of a recession.
It's important to note that a lot of people saw this coming for a long time.
The yield curve has been flattening, largely due to the fact that interest rates have been rising.
We talk a lot about investor fears and investor sentiment. That pays into it a lot.
When you think about an investor, if you're scared about the economic growth for the next
10 years, you're going to buy a 10-year note, something that locks up your money with a
guaranteed rate of return for a long period.
What that does is, it pushes down rates on the earlier notes, which causes the Fed to
raise the rates on those notes to try to get more investors to buy into the shorter-term notes,
which in turn raises those rates and causes an inverse yield curve.
When I think about it, I don't like to think about it as being a predictor of a recession
as much as it is a predictor of the economic conditions that make a recession more likely.
Ultimately, all it's doing is reflecting the fears and concerns that we have as investors.
Hill: When I hear the indicators are that a recession is more likely, in terms of stocks,
as someone who is not looking to invest in three-year bonds, five-year bonds, 10-year bonds,
I'm just not -- as someone interested in stocks, when I think about that, one of
the first places that my mind goes is discretionary spending stocks.
For me, the classic example is Dave & Buster's.
I look at Dave & Buster's as a business that almost certainly is doing better in booming
economic times than in recession times.
Does the increased likelihood of a recession affect your thinking at all as an investor?
Even so far as, "These stocks I was looking at, I'm going to put them on the back burner
and I'm going to pay a little bit more attention to these other stocks that I think might do
better during a recession."
Flippen: I had a great conversation with my colleague Jim Mueller today.
He talked a bit about that same thing.
We look at the economy and we think, "Oh, the economy is going to do poorly.
I'm not going to buy into discretionary stocks."
But it's important to remember that we're long-term investors.
As Jim pointed out, a recession, even the Great Recession, doesn't last three to five years.
You don't see something that's protracted that long. The stocks all made comebacks.
So, I agree with you to the extent that it doesn't really matter to me.
I'm going to be buying all the way to the bottom.
I do think that it's interesting when you think about the different plays you can make
in a market that is maybe in the later stages of an economic cycle vs. very early on.
For example, very early on, buying into the homebuyers like Toll Brothers; and the later stages,
maybe not buying into Dave & Buster's.
But ultimately, as long as you're buying into stocks and companies that you're confident
about, and you're planning on holding them over the long-term, blips like recessions,
which really are blips in the long run -- Hill: In the short-run, though, boy, they hurt!
Flippen: In the short run, they're very hard to deal with.
I think it's important to think back to the recession that we saw in 2008.
People will say, "Oh, the yield curve inversed before that recession. It's a predictor of the recession."
You'll note that the yield curve inversed in December 2005, almost three full years before the recession.
And it was more of a reflection of the fact that the Fed was rising the short-term rates
because they saw low rates were causing a bubble in the housing market, and they were
trying to deal with that. It was a representation of those consumer fears.
The yield curve itself does not cause the recession. It's a symptom of a larger problem that we're seeing.
-------------------------------------------
New Dino Rivals Giant Surprise Dinosaur Egg Jurassic World Fallen Kingdom Dinosaur Toys Unboxing - Duration: 8:11.
okay today we have a giant surprise egg we have drastic world dinosaur
for them and I'm gonna have my help Dino helpers help me open them up okay
Dino helpers are you excited
New Dino Rivals Giant Surprise Dinosaur Egg Jurassic World Fallen Kingdom Dinosaur Toys Unboxing
whoa what is this Oh No look at that it's Dino right to
look at kevinator what do you think t-rex okay in the Raptor what is our
next toy in the jegg okay t-rex what's our next toy in the giant egg let's see
it alright he's reaching in there oh cool it's the diner rivals
duel attack Triceratops what do you think t-rex is that awesome okay in the
Raptor what is next in the giant egg oh she's reaching in there what is it
Oh make a dual attack Stegosaurus cool what do you think about that in the
Raptor okay close in the giant egg whoa Oh check this out this is a big one
wow it's the title rivals bite plate Tyrannosaurus Rex what do you think
t-rex the t-rex is cousin okay in the Raptor what else was in that giant egg
pulling it out big one whoa awesome it's the Dino rivals make a doula cat
Texico my man what do you think in the Raptor
reaching in there oh she's reaching in there what is it oh she's reaching way
in there what are you thinking the Raptor okay t-rex what do we have next
Oh reaching way in there I think this is a big one what do you think about that
one you rack okay in the Raptor what else is in that giant egg she's reaching
win there what can I be whoa what is that oh cool it's the ground in the
Raptors that your cousin do you like that one
awesome t-rex what else was in that giant surprise egg he's reaching way in
there what is that
tricera tracker look they're trying to get your mom what do you think about
that okay in the rafter what else was in that giant egg
oh she's reaching what in there we must be getting near the end t-rex
tracker what do you think about that in the Raptor t-rex was there anything else
in that giant egg Raptor copter with Velociraptor blue what do you think
about that t-rex okay in the Raptor what else was in that
giant egg is it empty she's reaching for something there must be something else
left in there oh whoa let's see Wow hold that out
it's a Dino rivals Tyranno höllerer what do you think about that okay t-rex what
else was in that giant egg oh is it empty uh-uh
oh cool check it out it's the Dino rivals oh and baby blue okay in the
Raptor the egg empty go ahead let's take a look in there oh I think she's getting
something oh no she's gonna fall in the air
No check that out it's merged I know rifles mercenary and they work with on
awesome okay in the rapture what else was in that egg breach in the air is it
empty pulling something out what is it check it out it's the destructive swords
that lock the surahs set what do you think about that okay in the Raptor was
there anything else in that giant egg oh she's getting something what is this
whoa check it out the destructor soars Pteranodon awesome what do you think in
the Raptor oh good that was totally awesome if you guys enjoyed that you got
over a thousand videos check out my channel or if you want more fun
following Kingdom videos check out the playlist at the end of this video
what do you guys think was that awesome
in today's secret word is the word
go ahead put that in the comment section down below the video click the subscribe
button below for a lot more fun video also click the bell button to be
notified every time I make a new video click the boxes below for a lot more fun
videos and if you want to see even more go ahead and click the subscribe button
-------------------------------------------
3 Top Healthcare Stocks After #ASH18 - Duration: 25:45.
Shannon Jones: Welcome to Industry Focus, the show that dives into a different sector
of the stock market every day. Today is Wednesday, December 5th, and we're talking Healthcare.
I'm your host, Shannon Jones, and I'm joined via Skype by healthcare guru Todd Campbell.
Todd, how are you? Todd Campbell: I'm doing well, Shannon!
I'm excited about today's show. We're going to talk about one of the most highly anticipated
events of the year in healthcare. I think we're going to have some good takeaways here
for our listeners. Jones: I agree. I am equally as excited.
For our listeners that are new to the healthcare space, there are several big major medical
conferences that both the scientific community and investors watch anxiously. This one in
particular is ASH, the American Society of Hematology annual conference,
happening this year in San Diego. Todd, I don't know about you, this is actually
one of my favorites. If you think about between ASH, you've also got the JP Morgan Healthcare
Conference that happens in January. You've also got ASCO, American Society of Clinical Oncology.
That one happens around mid-year. Of the three, I love the big medical conferences the most.
JPM to me is more of a horse and pony show. You get some interesting presentations
on the business end of things. But for me, I love the science that comes out of conferences, just like ASH.
Campbell: Yeah, at JPM, there's a lot of rah-rah presentations.
"Look how great we're doing!" But you really oftentimes get some big news breaking like
mergers and acquisitions, sometimes they'll update their forecasts for the year, you might
get preliminary earnings data. Shannon, I'm sure you and I will be covering that in a
lot of detail because that happens relatively soon, in the first week of January.
The American Society Hematology conference, that is the study of things associated with
the blood, hematology. Usually, what ends up happening, these companies with clinical
stage and commercial stage drugs, they're running studies for blood cancers,
bone marrow cancers, hemophilia studies, sickle cell disease studies. And as they get interesting trial data,
they want to, of course, present that information out to all the industry participants.
Not just reporters, but we're talking actual scientists and doctors who are taking care
of these patients. So, yes, you're right, this is a really fascinating
event to watch. Oftentimes, you'll get data that is quite remarkable. Over the course
of the last few years, blood cancers especially have seen remarkable advances. We've talked
on the past on the show about CAR-Ts. We're going to talk about one in a few minutes.
This is a great show. I'm looking forward to diving into some of these companies and
explaining some of our key takeaways. Jones: We're going to run down our top three
notable stories coming out of ASH. This is certainly not an exhaustive list. Certainly
check out fool.com to stay up to date on all the coverage related to ASH. We chose what
we consider our top three. Todd, let's dive into the first one.
This is probably a household name for many healthcare investors. The first company that reported
out results is Celgene, ticker CELG. Celgene, never disappoints, had a slew of data readouts at ASH.
There was actually one presentation in particular that caught many investors' eyes.
Todd, what can you tell us about that? Campbell: Possibly one of the most prolific
presenters here. Celgene is just a dominant force in multiple myeloma, and as a result,
oftentimes makes a lot of presentations here at ASH every year. This year was no exception.
They had the poll position presentation on Saturday for the drug that they developed
with Acceleron, which is Luspatercept. We talked about that on the show in the past
for beta thalassemia and myelodysplastic syndrome. I figure, we've already covered
that one. It's not as exciting as this other data that they released.
The one that really stood out to me was the information they divulged on liso-cel,
which is a CAR-T gene therapy that is best known for its development for non-Hodgkin lymphomas.
Jones: Let's just talk about CAR-T a little bit. I know we've talked about it quite a bit
on Industry Focus. For anyone who's new, CAR-T is really taking the healthcare world
by storm. On the simplest level, it's basically a treatment in which a patient's T cells from
their immune system are taken out, they are transformed -- supercharged, if you will --
and then put back into the patient's body via infusion. The idea is, now, you've got a supercharged
immune system that can go out and fight cancer. Liso-cel is another type of CAR-T. It's definitely
not the first. For those that have been following, Gilead and Kite put out their own CAR-T, and Novartis
was first to market. But liso-cel, many investors will more readily recognize it as JCAR017.
Celgene actually purchased Juno Therapeutics earlier in the year, I believe it was about
a $9 billion acquisition, it got this asset, and now, it's turning some heads at ASH this year.
Campbell: Up until this point, we've thought
of liso-cel as being a potential best in class because of some potential safety advantages
vs. the first two that made it to market -- Gilead's Yescarta and Kymriah from Novartis. That changes
a little bit today, though. At ASH, they presented data from a very small trial for its use in
chronic lymphocytic leukemia, or CLL. That's the most common leukemia that gets diagnosed
in adults. It starts off in the cells of the bone marrow in the cells that become white blood cells.
What this trial did is, it evaluated liso-cel
in chronic CLL, which is a form wherein the cells only partially mature. They don't completely mature.
Over time, those non-completely-matured cells crowd out normal white cells,
spill out into the blood, go into other parts of the body. There are about 20,000 newly diagnosed
cases of CLL every year. What this study was trying to figure out is, could liso-cel provide
a new treatment for patients who have taken the standard of care, which is Imbruvica,
and seen their disease return, they've relapsed, or they were refractory, they didn't respond
to Imbruvica. And in this -- again, small -- trial,
the results were pretty remarkable. 81% of patients responded. 43% of patients had a complete response.
Jones: And these are patients that were truly sick.
These are patients that had failed, at least five other therapies just getting
to this point. These were very sick patients. Another thing in CLL is, right now,
there's not a CAR-T therapy that's indicated for CLL, which I think is very smart strategically.
This particular drug initially and still is going after the lymphomas, just like the other
CAR-T therapies, but you see Celgene actually pivoting, and I think it's very smart, because
this could potentially be the first CAR-T in CLL.
Campbell: Right. If you look at the commercial performance so far of Yescarta and Kymriah,
it's been a little bit of an anemic launch so far since they've rolled out. Combined
sales between those two CAR-Ts last quarter was less than $100 million. People have been
worried about this all year. They've been saying, jeez, even if you get this on the
market for non-Hodgkin's, how much of the sales will they really capture? Does that
justify that big price that they paid to buy Juno earlier this year? This walks back some
of that worry. Now, you can look at it and say, ah, OK. Imbruvica does nearly $1 billion
per quarter in sales. It's the most widely used drug in CLL right now. So, there is an
opportunity, where you could now say, yes, the first approval may come in non-Hodgkin
lymphoma for this gene therapy, but in the future, if you could get this approval in CLL,
now I can begin to see why Celgene is forecasting that this could be a $3 billion
per year drug in peak sales. Jones: And $3 billion is one range.
I've heard some analysts say it could even go as high as $5 billion. I think that's a little bit
more aggressive. But it really underscores the fact, and we've talked about this in a
lot of shows, that Celgene needs a more diverse revenue stream. Celgene, up until this point
right now, has got about 63% of its revenue tied in one drug, Revlimid. Listen to last
week's show if you want to hear more about that. But this could be a huge, huge revenue
driver for the company if it works. Again, this was a very small study, early, Phase I study.
The key issue that I'll be watching for this drug,
let's assume that it gets approved in CLL. They key is, can Celgene figure out how
to get CAR-T from the very expensive inpatient setting to potentially having this drug in
the less expensive outpatient setting? CAR-T therapy right now, Todd, you talked about
just how low those sales launch numbers are. Pretty disappointing. I think, really,
it's because of the list price. You're talking about $375,000, upwards of $475,000 for treatment,
and that doesn't even include the supportive care that goes along with infusing patients
with CAR-T. So, not only do they need to get to the finish line of getting this drug approved,
they also really need to think about, how do we make this commercially viable?
Campbell: Yeah, $500 million price tags. The other thing to recognize is that the current
ones that are on the market right now are for very late line use in patients,
small patient populations that have gone through multiple treatments and failed to respond to them.
Not only do you have to figure out how to reduce the cost of these things so
that you overcome insurers' and other payers' objections to them, but also figure out how
to make them safe enough to be able to be used earlier in the treatment paradigm.
If you have a safe drug that can generate very high response rates, then you could actually
start to see, maybe there's a way to use this alongside Imbruvica. I think a trial might
be planned for that, actually, in the future. Or, maybe even compete against it in the earlier
lines of setting. To rein back little enthusiasm for it,
as we said, most likely scenario here is for an approval in 2020, and that will be for
non-Hodgkin lymphoma. CLL would have to be supplemental, most likely, and that probably
wouldn't come until after that. So, we're still talking a few years away in CLL.
Jones: Yeah. But, definitely a key storyline to watch here for Celgene moving forward.
We've talked about CAR-T cell therapy. Many investors are familiar with that. I think
a good segue is actually talking about the second company making headlines,
potentially something even more interesting than CAR-T. The company that is driving this is Regeneron,
ticker REGN, which many investors will be familiar with. They're actually going after
a new-ish type of cell therapy, something called bispecific antibodies. It's certainly
made some splashy headlines here at ASH, Todd. I must say, I was quite impressed when I saw
the data on this one. Campbell: Very small sample size.
We'll get to that. But, yeah, incredibly impressive. Investors, what you really have to recognize,
we're always trying to figure out, what's the next big thing as far as mechanism of action
that people are going to be talking about. I think bispecific antibody therapies
could very well be what you're going to want to be focusing on in 2019. You're going to
hear more and more about these as we go. Essentially, what we're talking about is an
evolution of the tried-and-true, well-established monoclonal antibody programs that have been
around for a long time. They're bispecific because they can hit two or more cell service
targets at the same time, using the same drug, not using two separate monoclonals but having it together
in one therapy. What's really interesting about this, and
we were just talking about CAR-Ts. One of the risks associated with that is getting them
safe enough to be able to use in the majority of patients' early line therapy.
REGN1979 and other bispecifics potentially could be safer to use in patients than CAR-Ts
because they don't cause cytokine release syndrome, which is a life-threatening event
that's been oftentimes seen in some of the use of some of these CAR-Ts. The drug that
Regeneron's developing, REGN1979 -- great year, right Shannon? [laughs]
Jones: [laughs] Wonderful year! Campbell: That binds to CD3, which is on
the T cell of the immune system, and CD20, which is expressed on B cell tumor cells.
The idea here is, by binding to the T cell and binding to the CD20 on the tumor cell,
you're able to basically alert that immune cell to go target and destroy
that B cell cancer easier, better, more effectively. Jones: Yeah, and it could potentially have
a lower cost. We talked about the cost of CAR-T. Bispecifics could have a much lower
manufacturing cost associated with it, in addition to the potential better safety profile.
Let's talk about efficacy, Todd. Granted, this is a very small study. We should always
caveat that. But they were actually able to have a 100% overall response rate in a particular
type of lymphoma. What can you tell us about that, Todd?
Campbell: That's just stupid good, right? It's amazing! It's crazy! They were evaluating
in non-Hodgkin lymphoma, specifically two different types. Follicular lymphoma was the one
that saw that 100% response rate. Follicular lymphoma is not necessarily incredibly common.
There are about 15,000 new cases per year in the United States. Typically, patients
respond pretty well to the existing therapies that are out there right now. I think the
five-year survival for follicular is right around 88%. But for those patients that don't respond well
to the existing therapies, there still is a very big need for new treatment approaches.
Maybe, maybe, this will be that new treatment approach.
We had 10 patients that were studied in this early stage trial. As you mentioned,
100% of them responded to the treatment. 80% of them, Shannon, were complete responders.
That's just remarkable. Jones: I think the key here will be looking
at durability of response moving forward. These were pretty heavily pretreated patients.
Another thing to watch is, most people will know, Regeneron just got FDA approval.
Kind of late to the checkpoint race, but they did just get approval for the checkpoint Libtayo.
It'll be interesting to see Regeneron potentially partner their PD-1 checkpoint inhibitor with this drug,
and what the results could be. For those that aren't familiar,
checkpoint inhibitors have ushered in this new wave of immunotherapy, and have had some impressive results,
but they don't work in everyone. Two, looking at the durability of response
and who responds to that, has been a big question mark. If you could pair these two together
and get durable responses, I think this makes Regeneron certainly a stock to watch.
Campbell: I think that's what Regeneron's goal is. Now, they've got this PD-1 drug.
The way they're looking at it is saying, "Hmm, what indications are PD-1s approved for yet?
Maybe we can develop other drugs internally, partner those two drugs up, and be able to
outmaneuver some of the other competitors out there and establish a foothold in these
big markets." I think a trial actually started already that matches these two drugs up.
We're going to want to watch that very closely. We're also going to watch 2019, Shannon,
because Regeneron says that they are going to kick off what they think could be a registration-ready trial,
a Phase II trial, so they're going to go after an accelerated approval, in follicular lymphoma.
We're going to want to keep a really close eye on that, as well.
Jones: You've also got some other bispecifics out there. Amgen also has a bispecific,
as well as Pfizer. I think 2019, as you mentioned, Todd, will definitely be the year of the bispecifics.
CAR-T, old news, 2018. 2019, definitely bispecifics. Let's turn our attention to the last notable headline,
certainly not the least. Todd, a wise person once said, "If at first you don't succeed,
try, try again." I don't know who said that, but I think they were talking about
Global Blood Therapeutics, ticker GBT. When you talk just talk about the share price reaction
to news that happens at these medical conferences, this company saw shares skyrocket almost 50%
on one day. I think they closed right around $46 a share, based on a Phase III study and
a regulatory update on a product that has had mixed results.
Campbell: The drug that we're talking about here with Global Blood Therapeutics --
and you're right, we saved the best for last. $30 to $47 from Friday to where we are this morning.
That's just a crazy move in this company's stock. The drug is Voxelotor --
easy for me to say. We'll just call it Vox. Jones: It's Vox.
Campbell: Alright, we're calling that Vox. It sounds like something out of the Jurassic era.
Anyways, that's a once-daily oral therapy for sickle cell disease.
Sickle cell disease is a life-threatening, chronic disease, onset typically in childhood.
Over time, it can starve organs of blood, it can cause stroke. Unfortunately, patients have
a shortened lifespan with sickle cell disease, and they can also suffer from extremely painful
vaso occlusive crises that land them in the hospital and force them to rely on opiates
to manage their pain. There is a massive need for new treatments for sickle cell disease.
And, based on the data we saw at ASH and news that came out of the FDA at the same time,
it appears that this drug may be on the fast track for helping out these patients.
Jones: Absolutely. On the regulatory front, the FDA, according to the company, has agreed
to accept the company's request to put Vox on this accelerated approval pathway as a
treatment for sickle cell disease. For those that have been following this particular company,
it's quite fascinating, because sickle cell disease, huge unmet need. There have been
multiple attempts to stop and inhibit what the FDA considers the benchmark of approval,
which is these pain crises that happen. That's really what most drug companies try to go after.
GBT, I mentioned, had some mixed results.
But what they have finally gotten to at this point is now potentially an endpoint that
the FDA likes. With that, you've got now the FDA saying, "OK, let's move forward with this
on an accelerated basis." The key here is, can Vox actually have long-term clinical benefit?
Even though the stock certainly responded tremendously to the data that came out of
this conference, the risk associated with this stock is probably the highest of these stories,
just because you want to see long-term clinical benefit. As I understand it,
Vox is actually now going after an endpoint that may have not as much clinical benefit for patients.
Campbell: You have to understand, too,
that if they are successful in getting this drug across the finish line, theoretically,
it's disease-modifying. What it would do is, it helps prevent the sickle-ing of those cells
by re-oxygenating those cells so that they don't form that inflexible sickle shape.
That part of this drug is fascinating to me. The trial that we saw data from at ASH was
really a dose escalation study. It wasn't meant to serve as a registration-ready trial.
However, in June, they reported preliminary data from a part A of this trial. That part A
trial data was that 58% of Vox patients who got a 1,500-milligram daily dose of it
saw an increase of one gram per deciliter in their hemoglobin at week 12. Only 9% of
patients that were given a placebo saw such an improvement. So, the thinking here is,
if we are able to produce more red blood cells that work right, work correctly, then perhaps,
perhaps, we then reduce the potential for those vaso occlusive crises. We also maybe
delay disease progression and these patients can live longer. Like you said, that's not
proven yet. This is all still theoretical. At ASH, they updated the data from Part A.
Now, 65% of patients who took that 1,500-milligram dose saw at least a one gram per deciliter
improvement at 24 weeks. That was vs. 10% on placebo. They also reported some data from
Part B, which was also looking at the 1,500-milligram dose. 55% of patients saw that one-gram improvement,
as well. So, it definitely seems that this works better than placebo, as far as
being able to get healthier red blood cells for patients. Whether or not that actually improves
quality of life and reduces the risk of early death remains to be seen.
Jones: Yeah. So, this is definitely a stock to watch moving forward. Again, the assumption is,
if you can increase the capacity of blood to deliver more oxygen to tissues, you could
theoretically protect organ function and reduce the risk of stroke in patients with sickle
cell disease. It's not necessarily a new scientific paradigm.
There was a study done back in the late 90s that I pulled up that did demonstrate that
blood transfusions, at least, were increasing hemoglobin levels and reducing stroke frequency
in children with sickle cell disease. So, it certainly could be a follow-up to that.
We'll have to wait and see on Global Blood therapeutics. Certainly keep your eyes on that,
but definitely some uncertainty. All in all, ASH has proven to be a great idea
generator, at least for me. Todd, I don't know about you. But, that does take us right
into JPM coming up in a few weeks. It'll be really interesting to see what other ideas
we get out of that, too. Campbell: Absolutely. I'm looking forward
to talking with you more about that in a few weeks.
Jones: Can't wait! That's it for this week's Industry Focus: Healthcare show. As always,
people on the program may have interest in the stocks they talk about, and The Motley Fool
may have formal recommendations for or against, so don't buy or sell stocks based
solely on what you hear. This show is produced by Austin Morgan. For Todd Campbell, I'm Shannon Jones.
Thanks for listening and Fool on!
-------------------------------------------
Aviation News, Space Stories, Drone Dispatches, UFO Rumours #19 - Duration: 5:24.
For more infomation >> Aviation News, Space Stories, Drone Dispatches, UFO Rumours #19 - Duration: 5:24. -------------------------------------------
Cómo Tener Relaciones Personales Más Seguras Y Positivas | 30K Coaching - Duration: 4:32.
It may seem silly to those who relate safely without difficulty,
but this is not something that happens spontaneously for everyone. I am Sandra Burgos and
Today I am going to guide you so that you can learn to relate in a safe and positive way. Stay!
Social intelligence is the set of competences that we are most passionate about in this channel. If you
I want to grow yours every day little bit more, subscribe. We will not stop
learn new things about social skills, body language, interpretation of
people…
If it's not your first time around here, you know I like to dig for interesting bits
of applicable knowledge between the minds brighter, that's why I usually recommend
some reading from time to time Today I want recommend the book "The World In Your Hands",
of Elsa Punset, which is the source from which I have extracted what I come to tell you today.
I'll leave the link to the book in the box information: https://www.amazon.es/mundo-tus-manos-inteligencia-Divulgaci%C3%B3n/dp/8423349721/ref=as_sl_pc_qf_sp_asin_til?tag=30kcoac-21&linkCode=w00&linkId=a69edbc67391c1077bf146168e62e34d&creativeASIN=8423349721
Elsa Punset shares 4 tips to relate in a more secure and positive way. We see?
1 Anchor your positive experiences
Make a list of the moments or stages where you felt safe in a relationship,
and repeat the behaviors that made you feel like that. If you do not have many memories
of this type, look at a person model that shows a "safe" way of relating,
Observe it and put some of your resources.
2 Practice good principles for the resolution of conflicts
When you have a conflict with a person dear, avoid walking away or scare. Instead
of that, focus your attention on the resolution of the conflict; for example, using the
"Message from the me". If it does not sound good this, the messages from the self are a form
to express ourselves in which we talk about how We feel without blaming the other person.
Tell me in a comment if you would like a video about this.
3 If what you want is a stable relationship, distinguishes people's smoke signals
with avoidant styles
Many people with ways of relating avoidant or distant use the resource
of keeping the couple in uncertainty. If you agree to live in that uncertainty
when in reality you are clear that you would like a stable relationship, you will be placing
in an uncomfortable place and most likely disappointing for you Look also at
if that person sends you mixed messages, if he says intimate things when he talks about you,
what is your sentimental history ...
4 People reveal almost everything about of themselves at the beginning of a relationship
Listen, keep your eyes open and be consistent in your choice. If it is the kind of person
what you want in your life, go ahead. But take that decision consciously.
Go now through the comments section and tell me: have you ever been immersed
in a toxic relationship? If so, how much Have you put up with that situation? And how
you have finally made the decision to move page? I would like very much to know your experience.
If you liked this video, click on "I like it" and share it in your networks
social. And if you want to receive more workouts like this, every Tuesday, in your email,
subscribe for free to my weekly newsletter http://www.30kcoaching.com/lista
Remember that you have much more at your reach of what is necessary to be happy. The decision
it's yours!
-------------------------------------------
प्रैक्टिस सेट VERG-1 MPTET | CTET 2018-MODEL PAPER | PRACTICE SET PAPER |SAMPLE PAPER SET 1 - Duration: 16:44.
VIJAY ACADEMY
-------------------------------------------
Best 5 Amazing High Tech Gadgets Under $20 | Latest 2019 High Tech Gadgets - Duration: 4:07.
-------------------------------------------
Standard Form pt 1 - Maths For Science - Succeed In Your GCSE and IGCSE - Duration: 8:30.
this video is brought to you by succeedschool.com with complete lessons and
resources assessments learning plans and schemes of work for students parents and
teachers for revision for catch-up or just to get ahead in class visit succeed
school.com now for your free trial lessons succeedschool.com learn to
succeed hey class I'm mr. Thornton and I'm going to help you succeed in your
GCSE and I GCSE in the first video of this two-part lesson on standard form in
science I'm going to explain what standard form is standard form is a real
cornerstone of maths in science it's when we write numbers like 3 times 10 to the
8th rather than writing them out in full like this it makes it way easier to
represent really big and really small numbers whether that's biologists
talking about the size of viruses chemists calculating how many atoms a
formula of a substance contains or physicists measuring the distances to
other galaxies standard form once you know how to use it actually makes these
numbers much easier to work with in this first video I'm going to explain exactly
what standard form is for those who don't know but if you're already
familiar with the notation then you can skip straight to the time code on screen
right now to see how things are a little simpler in science than they are in
maths in the second video which you can see by clicking here I'll explain how to
use standard form in science on pretty much any modern scientific calculator so
if you're still watching this bit let me explain what standard form is
essentially it's just a shorter way to write numbers and that's useful because
we often deal with very big or very small numbers in science I'll start with
a nice simple example though so it's easy to keep track of what's going on
let's say we wanted to write 20,000 meters in standard form standard form
uses powers of 10 to simplify things for example 10 squared that is 10 to the
power 2 is 100 10 to the power 3 is 1,000 and so on 10,000 is just 10 to the
power 4 so we could write 20,000 as just two times 10 to the power 4 will
usually just say 2 times 10 to the 4 instead of 2 times 10 to the power of 4
it means the same thing also notice that 20000 is the number 2
with 4 zeros after it if we had 200,000 it has 5 zeros after it
so this would be 2 times 10 to the 5 the number of digits after the first digit
tells us the power of 10 for example the number 3 times 10 to the 8th which I
mentioned at the start of the video is just a 3 with 8 zeros after it like this
this is actually the speed of light in meters per second round to a few
significant figures if you take a look at this number line you can see that as
we multiply by 10 our power of 10 just increases by 1 10 to the power 1 is just
10 10 to the 2 is 100 10 to the 3 is 1,000 and so on this number line extends
the other way too as we move right on the line we multiply by 10 so as we move
left we do the opposite function and divide by 10 10 to the power 0 is the
same as 10 to the power 1 divided by 10 that's just 10 divided by 10 which is
equal to 1 in fact any number to the power 0 equals 1 as we move to the left
on the number line we keep dividing the previous number by 10 so 10 to the power
minus 1 is 1 divided by 10 that is nor point 1 10 to the minus 2 is naught
point naught 1 10 to the minus 3 is naught point naught naught 1 and so on
notice that in the same way that positive powers of 10 told us how many
digits were after the first number negative powers tell us how many digits
are before the first number including the 0 on the left of the decimal place
so that's what they'll teach you in maths but here's where science differs
we use prefixes like kilo meaning a thousand and milli meaning one
thousandth to modify our units of measurement these prefixes can be
represented as of 10 but instead of having a prefix for
every single power increase we skip over some powers and mostly increase or
decrease powers in multiples of 3 like this this table of prefixes can be
downloaded for free from the succeedschool.com free trial the link is in the
description this isn't a list of all the prefixes scientists use but it does
cover all the ones you need to know for GCSE and IGCSE as you can see Giga
meaning a billion is 10 to the 9 mega meaning a million is 10 to the 6 kilo a
thousand is 10 to the 3 10 to the 0 has no prefix because it's just equal to 1
as we've already seen milli 1000 is 10 to the minus 3 micro which is 1 million
is 10 to the minus 6 nano which is one billionth is 10 to the minus 9 and pico
which is one trillionth is 10 to the minus 12 you'll find in science we don't
need to use standard form in his rigorous away as you do in maths you
still can if you like but things are a bit more flexible in a couple of key
ways let me show you this laser produces light waves with a wavelength of 532
nanometers roughly in the middle of the visible spectrum one nanometer is ten to
the minus nine meters so we could write this value as 532 times 10 to the minus
9 meters your maths teachers would probably prefer you to then know to
rewrite this as 5.32 times 10 to the minus 7 meters and to be able to do that
without a calculator and if you can great but in science you
don't need to almost every scientist would just write 532 nanometers as 532
times 10 to the minus 9 and be done with it this is a better system for us
because 10 to the minus 7 doesn't have a prefix but 10 to the minus 9 does nano
plus we can use a calculator in science something which I'll cover more in the
next video if we wanted to write 20,000 meters
in maths we would probably write it as 2 times 10 to the 4 meters but in science
we know a thousand meters that is 10 to the 3 meters is a kilometer so 20,000
meters is just 20 kilometers so most scientists would write this distance is
20 times 10 to the 3 meters this matches exactly with the way we describe numbers
in our everyday language with values increasing into thousands then millions
then billions and so on matching exactly with kilo mega and Giga the way
scientists use standard form is much closer to the way we talk about numbers
every day and not only is converting the numbers so that there's only a single
digit before the decimal point not necessary it can actually make
everything less clear so scientists generally just don't bother with this
debt and you don't need to either so that's how scientists use standard form
if you check the next video I'll show you how to type it into your scientific
calculator I hope that video really helps you if it did
it'll be great if you let me know in the comments remember to Like subscribe and
hit the bell to get a notification then next time I upload the video if you
check the description i've got links to my division guides and to snapquiz
that's my revision website and app and to succeedschool.com that's my website
with full lesson plans schemes of work and end of unit tests for both teachers
and students I've also got links in the description to my Twitter my Instagram
my patreon if you want to support the channel and there's links to my other
YouTube channels not school and place you can also click just here to
subscribe to this channel and you can click here to check out this related
video good looking new GCSE use anti GCSEs and thanks very much
-------------------------------------------
যে বক্তার জিব্বা কেটে নেয়া হবে | New Short Waz | Shaikh Abdur Razzak Bin Yousuf New | 2018 [FHD] - Duration: 1:27.
AK Computer Network
Have Done This Video
-------------------------------------------
আল্লাহ্র মুখা মুখী দাড়িয়ে | New Short Waz | Shaikh Abdur Razzak Bin Yousuf - Duration: 3:42.
AK Computer Network
Have Done This Video
Không có nhận xét nào:
Đăng nhận xét